First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease.
- 24 April 2009
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 61 (3), 197-203
- https://doi.org/10.1111/j.1600-0609.1998.tb01084.x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- Early diagnosis of low grade malignant lymphoma and chronic lymphocytic leukaemia. Verification of morphologically suspected malignancy in blood lymphocytes by flow cytometryEuropean Journal of Haematology, 1996
- HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic LeukemiaAnnals of Internal Medicine, 1996
- Fludarabine‐related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemiaBritish Journal of Haematology, 1995
- Recurrence of Autoimmune Thrombocytopenia after Treatment with Fludarabine in a Patient with Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1994
- Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphomaAnnals Of Oncology, 1993
- Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.Journal of Clinical Oncology, 1991
- Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukemiasEuropean Journal of Immunology, 1990
- Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood, 1989
- Primer-directed enzymatic amplification of DNA with a thermostable DNA polymeraseScience, 1988